Compare ICHR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | CRVS |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2016 | 2016 |
| Metric | ICHR | CRVS |
|---|---|---|
| Price | $48.43 | $17.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $40.67 | $28.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $947,652,000.00 | N/A |
| Revenue This Year | $16.08 | N/A |
| Revenue Next Year | $11.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $13.15 | $2.54 |
| 52 Week High | $55.00 | $26.95 |
| Indicator | ICHR | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 51.83 |
| Support Level | $15.70 | $16.15 |
| Resistance Level | N/A | $26.95 |
| Average True Range (ATR) | 4.08 | 1.03 |
| MACD | -0.32 | -0.42 |
| Stochastic Oscillator | 55.63 | 41.60 |
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).